2-cyclopropyl-5-nitro-1H-benzo[d]imidazole | 51758-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-cyclopropyl-5-nitro-1H-benzo[d]imidazole
• 英文别名: 2-Cyclopropyl-5-nitro-benzimidazol；2-cyclopropyl-5-nitro-1H-benzimidazole；2-cyclopropyl-5-nitro-1H-1,3-benzodiazole；2-cyclopropyl-6-nitro-1H-benzimidazole
• CAS: 51758-97-5
• 化学式: C₁₀H₉N₃O₂
• mdl: MFCD08691249
• 分子量: 203.2
• InChiKey: QKWXLTTXVGJHOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-cyclopropyl-5-nitro-1H-benzo[d]imidazole 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 以1.1 g的产率得到2-cyclopropyl-1H-benzo[d]imidazol-5-amine
  参考文献：
  名称：

  INDOLE DERIVATIVE, PREPARATION METHOD THEREOF, AND USE THEREOF IN PHARMACEUTICAL DRUG

  摘要：

  公开号：

  EP3339305B1
• 作为产物：
  描述：

  4-硝基邻苯二胺 、 环丙甲酸 在 水 、 氯化钠 、 magnesium sulfate 作用下， 反应 14.0h， 以6.5 g of a brown oil are obtained的产率得到2-cyclopropyl-5-nitro-1H-benzo[d]imidazole
  参考文献：
  名称：

  N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof

  摘要：

  本发明涉及一般式（I）的化合物，其中n，X1，X2，X3，X4，Y和W的定义如本文所述。本发明还涉及制备所述化合物的方法以及它们的治疗用途。

  公开号：

  US20130046095A1

文献信息

• N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof
  申请人：DUBOIS Laurent

  公开号：US20080146646A1

  公开（公告）日：2008-06-19

  The invention concerns compounds of general formula (I), wherein n, X 1 , X 2 , X 3 , X 4 , Y and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.

  这项发明涉及通式（I）的化合物，其中n、X1、X2、X3、X4、Y和W的定义如本文所述。该发明还涉及一种制备所述化合物及其治疗用途的方法。
• Synthesis of condensed heterocycles via cyclopropylimine rearrangement of cyclopropylazoles
  作者：Yury V. Tomilov、Dmitry N. Platonov、Aleksandr E. Frumkin、Dmitry L. Lipilin、Rinat F. Salikov

  DOI：10.1016/j.tetlet.2010.07.096

  日期：2010.9

  Thermal cyclopropylimine rearrangement of cyclopropylazoles into condensed heterocycles and factors affecting the regioselectivity and conversion are reported. A method of conducting the reaction in the absence of solvents is developed. A series of 2-cyclopropylazoles, including novel examples, is synthesized and their transformations into the corresponding condensed heterocyclic compounds (2,3-dihydro-1H-pyrroles

  报道了环丙基唑热环丙基亚胺重排成稠合杂环和影响区域选择性和转化的因素。开发了一种在不存在溶剂的情况下进行反应的方法。合成了一系列2-环丙基唑，包括新颖的实例，并将其转化为相应的稠合杂环化合物（2,3-二氢-1 H-吡咯和6,7-二氢-5 H-吡咯[2,1- b噻唑鎓盐）进行了研究。
• Novel benzimidazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030181730A1

  公开（公告）日：2003-09-25

  This invention provides compounds having the structure: 1 wherein each of R 1 , R 2 , R 3 and R 9 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R 1 is present, R 3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R 3 is present, R 1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R 4 , R 5 and R 6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR 7 , —CN, —COR 7 , —CO 2 R 7 , —CON(R 7 ) 2 , —OCOR 7 , —SR 7 , —N(R 7 ) 2 , —NR 7 COR 7 , —(CH 2 ) n OR 7 , —(CH 2 ) n N(R 7 ) 2 , —(CH 2 ) n NR 7 COR 7 , wherein n is an integer from 1 to 4; and wherein each of R 7 and R 8 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.

  本发明提供具有结构的化合物：1其中R1，R2，R3和R9中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 酰基，苯基，取代苯基或杂环基; 其中每个虚线代表单键或双键，前提是如果R1存在，则R3不存在，并且在位置3处的N和位置2处的C之间有双键，在位置2处的C和位置1处的N之间有单键，如果R3存在，则R1不存在，并且在位置1处的N和位置2处的C之间有双键，在位置2处的C和位置3处的N之间有单键; 其中R4，R5和R6中的每一个都是独立的H，F，Cl，Br，I; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 苯基，取代苯基，杂环基，—OH，—OR7，—CN，—COR7，—CO2R7，—CON(R7)2，—OCOR7，—SR7，—N(R7)2，—NR7COR7，—(CH2)nOR7，—(CH2)nN(R7)2，—(CH2)nNR7COR7，其中n是1到4的整数; 其中R7和R8中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; 苯基或取代苯基。 这些化合物对克隆的人类α2受体具有选择性，并可用作镇痛，镇静或麻醉剂。
• Benzimidazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06403626B1

  公开（公告）日：2002-06-11

  This invention provides compounds having the structure: wherein each of R1, R2, R3 and R9 is independently H; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R1 is present, R3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R3 is present, R1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R4, R5 and R6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR7, —CN, —COR7, —CO2R7, —CON(R7)2, —OCOR7, —SR7, —N(R7)2, —NR7COR7, —(CH2)nOR7, —(CH2)nN(R7)2, —(CH2)nNR7COR7, wherein n is an integer from 1 to 4; and wherein each of R7 and R8 is independently H; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.

  本发明提供了具有以下结构的化合物：其中R1、R2、R3和R9中的每一个独立地是H；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；C3-C7环烷基或环烯基；酰基，苯基，取代苯基或杂环基；其中每个虚线表示单键或双键，但如果R1存在，则R3不存在，并且在位置3的N和位置2的C之间存在双键，在位置2的C和位置1的N之间存在单键，如果R3存在，则R1不存在，并且在位置1的N和位置2的C之间存在双键，在位置2的C和位置3的N之间存在单键；其中R4、R5和R6中的每一个独立地是H、F、Cl、Br、I；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；C3-C7环烷基或环烯基；苯基，取代苯基，杂环基，—OH，—OR7，—CN，—COR7，—CO2R7，—CON（R7）2，—OCOR7，—SR7，—N（R7）2，—NR7COR7，—（CH2）nOR7，—（CH2）nN（R7）2，—（CH2）nNR7COR7，其中n是1到4的整数；其中R7和R8中的每一个独立地是H；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；苯基或取代苯基。这些化合物选择性地作用于克隆的人类α2受体，并且可用作镇痛、镇静或麻醉剂。
• N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof
  申请人：Sanofi-Aventis

  公开号：US07745467B2

  公开（公告）日：2010-06-29

  The invention concerns compounds of general formula (I), wherein n, X1, X2, X3, X4, Y and W are as defined herein. The invention also concerns a method for preparing said compounds and their therapeutic use.

  本发明涉及一般式（I）的化合物，其中n，X1，X2，X3，X4，Y和W如本文所定义。本发明还涉及制备该化合物的方法及其治疗用途。